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Abstract
Background: Mutation analysis of the neurofibromatosis type 1 (NF1) gene has shown that about
30% of NF1 patients carry a splice mutation resulting in the production of one or several shortened
transcripts. Some of these transcripts were also found in fresh lymphocytes of healthy individuals,
albeit typically at a very low level. Starting from this initial observation, we were interested to gain
further insight into the complex nature of NF1 mRNA processing.
Results: We have used a RT-PCR plasmid library based method to identify novel NF1 splice
variants. Several transcripts were observed with specific insertions/deletions and a survey was
made. This large group of variants detected in one single gene allows to perform a comparative
analysis of the factors involved in splice regulation. Exons that are prone to skipping were
systematically analysed for 5' and 3' splice site strength, branch point strength and secondary
structure.
Conclusion: Our study revealed a complex splicing pattern, generating a great diversity in NF1
transcripts. We found that, on average, exons that are spliced out in part of the mRNA have
significantly weaker acceptor sites. Some variants identified in this study could have distinct roles
and might expand our knowledge of neurofibromin.
Background
The genome of higher eukaryotes codes for most of its
proteins through short coding sequences (exons) inter-
rupted by non-coding sequences (introns). These inter-
vening sequences must be removed precisely after
transcription of the gene, a process called splicing. Splic-
ing is carried out by the spliceosome, a large complex con-
sisting of proteins and small nuclear RNAs (snRNAs) [1–
3]. RNA splicing is dependent upon the identity of nucle-
otide sequences at the exon/intron boundaries. The 5'
boundary or donor site of introns in most eukaryotes con-
tains the dinucleotide GU, while the 3' boundary or accep-
tor site contains the dinucleotide AG. These GU-AG
motifs are merely parts of longer consensus sequences
that span the 5' and 3' splice sites. With the exception of
the conserved canonical GU and AG at the 5' and 3' splice
sites, splice site sequences may contain several deviations
from the consensus. The match of a splice site to this con-
sensus reflects the strength of the site. In addition, a third
conserved intronic sequence that is known to be function-
ally important in splicing is the branch point, located 10–
50 nucleotides upstream from the AG dinucleotide. The
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branch point is characterised by a rather weak consensus
sequence YURAY [4]. In the first step of splicing the 2' hy-
droxyl of an adenosine of the branch point attacks the
phosphate at the 5' splice site, producing a free 5' exon
and a lariat intermediate. During the second step, the 3'
hydroxyl of the 5' exon attacks the phosphate at the 3'
splice site, yielding a ligated mRNA and a lariat intron.
Now that the total human genome has been sequenced,
the surprising outcome is that differences between hu-
mans and other organisms are not reflected by the ge-
nome complexity. Alternative splicing might play a role in
this apparent discrepancy. Alternative splicing is an im-
portant mechanism to create protein diversity and to reg-
ulate gene expression in a tissue- or developmental-
specific manner. To understand the mechanism of alter-
native splice site selection the identification of all cis-act-
ing elements that contribute to the efficiency with which
splice sites are recognised must be taken into account.
These include 1) the strength of the 3' and 5' splice sites,
which can be calculated using the consensus values that
were determined by Shapiro and Senepathy [5] or by the
Splice Site Prediction program by Neural Networks
(SSPNN,  [http://www.fruitfly.org/seq_tools/splice.html]
) which takes more known sequences into account, 2) the
branch point sequences and 3) certain sequences such as
exonic splicing enhancers (ESE) that can activate the use
of a weak 3' splice site or elements such as exonic splicing
silencer elements (ESS) that inhibit splicing [1]. In addi-
tion to these cis-acting elements, exon length [6] and sec-
ondary structure have also been mentioned to play a role
in splicing [7].
Neurofibromatosis type 1 (NF1) is an autosomal domi-
nantly inherited disorder affecting one in 3500 individu-
als [8]. The gene spans 350 kb of genomic DNA and
encodes approximately 13 kb mRNA containing 60 exons.
Three exons (9br, 23a and 48a) are known to be subjected
to alternative splicing and these isoforms were also detect-
ed at the protein level with isoform-specific antibodies
[9,10]. Four additional alternative transcripts were de-
scribed (ex29-, ex30-, ex29/30- and the N-isoform) but no
further analysis at the protein level was reported [11,12].
During mutation analysis in the NF1-gene we disclosed
several additional splice variants in which specific exons
were skipped and that were also present in fresh lym-
phocytes of non-affected persons, albeit typically at a low
level [13]. Several other studies also report the existence of
lowly expressed splice NF1 variants. Some of these vari-
ants are more abundant when RNA is analysed from aged
blood or from blood that was kept at a non-physiological
temperature [13–16]. Starting from this initial observa-
tion, we were interested to determine the extent of aber-
rant and/ or alternative splicing in NF1. A RT-PCR
plasmid library was made to identify new NF1 splice var-
iants. We have made a survey of these variants and
searched systematically for a number of factors involved
in splice site selection aiming to explain the observed var-
iants.
Results and discussion
Identification of novel NF1 splice variants in normal cells
The entire NF1-coding region from two normal non-af-
fected individuals was amplified in 5 overlapping seg-
ments by RT-PCR according to Heim [17] starting from
fresh blood leukocytes. As expression of specific NF1 tran-
scripts can change due to environmental changes [13–
16,18], we extracted the RNA immediately after blood
drawing, allowing to identify splice variants that are not
induced by stress factors. Plasmid libraries were created
and 150 colonies per fragment were lysed and reamplified
with the same primers in order to search for the presence
of minor splice variants. The PCR products were digested
with a restriction enzyme and separated by electrophore-
sis on an agarose gel (Fig. 1). For the five fragments, a total
of 114 clones out of 750 colonies in total showed a differ-
ent restriction pattern. Sequence analysis of the inserts re-
vealed that these represented NF1 transcripts with specific
insertions/deletions. Some of these resulted from cryptic
splice site usage, others were found to have deletions pre-
cisely at the exon boundaries ('exon skipping'), very few
resulted from intron retention. All variants that were
found are summarised in Fig. 2. Transcripts containing
more than one change per single transcript were also iden-
tified. Some changes were in frame (14 variants, green in
Fig. 2) others were out of frame (32 variants, red in Fig. 2)
and hence would lead to a premature stop codon. All to-
gether, 46 different transcripts were detected. The number
Figure 1
Representative restriction pattern of eight colonies
of NF1-F4 digested with AvaII. (1)-(4), (7), (8): full length
NF1-F4, (5): NF1-∆ E30, (6): NF1-∆ [E30, E36/E37]
M123 4 567 8
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Figure 2
Schematic representation of all splice variants detected in five overlapping NF1 fragments. In frame events are
indicated in green whereas out of frame events are red. Transcript variants described in blue are identical to misspliced tran-
scripts, described previously for NF1 patients, caused by a genomic mutation. The number of colonies detected containing a
specific variant is indicated between brackets.
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of abnormal sized transcripts is not exhaustive as only 150
colonies per fragment were analysed (750 colonies in to-
tal). The frequency of each clone captured is indicated be-
tween brackets in Fig. 2. This frequency might indicate
that some NF1 transcripts are more abundant in blood, as
compared to rarer NF1 transcript variants. Some of these
variants have been independently observed by other
groups: NF1ins4a-2 [14–16], NF1∆ E4b [14–16], NF1∆ E7
[15,19], NF1∆ E29/E30 [11], NF1∆ E30 [11], NF1∆ E33
[16], NF1∆ E34 [16], NF1∆ E37 [15,16], NF1∆ E43 [16],
NF1-∆ 7605–7675 [16] and NF1∆ E45 [16]. Some of these
transcripts increased with time or cold shock [14,16]. It
has been shown that ~30 % of NF1 germline mutations
result in splicing errors [13,20]. The vast majority of them
are due to alterations outside the canonical AG/GT accep-
tor and donor splice sites. Some of the splice variants
identified in this study are identical to misspliced tran-
scripts formed by the mutant allele carrying a specific mu-
tation in NF1 patients (11 variants, blue in Fig. 2). For
example, the NF1-∆ 2618_2850 transcript was found in a
NF1 patient carrying an IVS16+3del6 [13] mutation. In
this patient mutation at the splice donor of exon 16 leads
to the constitutively activation of the cryptic donor
present in exon 16 at position 2618 that normally is used
in only a minor proportion of the transcripts.
Role of splice site strength in splice site selection
Intensive effort has already been made to understand the
mechanisms involved in splice site selection. Because we
detected such a large group of variants in one single gene,
a detailed examination of the different parameters that
play a role in alternative splice regulation could be per-
formed and compared statistically. Early splice site choice
in mammals involves protein-protein interactions across
the exon, as is proposed in the exon definition model of
Berget [21]. Exon definition is mediated in part by SR pro-
teins bridging between the small nuclear ribonuclopro-
tein (snRNP) U1 at a downstream 5' splice site and the
U2AF heterodimer at the upstream 3' splice site. First we
calculated the strength of the 5' and 3' splice sites of all
constitutive and alternative exons and of all deletions and
insertions reported in this study. Calculations were per-
formed using the Splice Site Prediction by Neural Net-
work (SSPNN,  [http://www.fruitfly.org/seq_tools/
splice.html] ) program (Table 1). In general, sequences
that show a better match to the consensus sequences, in-
dicated by a higher calculated score, are considered to be
'strong', as specificity of the splicing reaction is mediated
in part by RNA-RNA interactions between these sequences
and snRNA molecules. The calculated scores demonstrate
that deletions or insertions sometimes occur at strong
cryptic splice sites (e.g. the NF1-∆ 2618_2850 variant),
whereas in a few cases no or only a weak consensus splice
site was found (score of < 0.7: underscored in Table 1, e.g.
NF1-∆ 5701_6946). The latter might result from aberrant
splicing or PCR artefacts.
We wanted to examine whether an association exists be-
tween the observed splicing pattern and splice site
strength. To this end, a comparison of the scores was
made between those single exons that were spliced out in
a fraction of the mRNA (bold in Table 1), including the al-
ternative exons 9br, 23a and 48a, and the mean values for
all NF1 exons (Table 2). Skipping of more than one exon
probably involves other factors and mechanisms than
those based on splice parameters alone. The exon defini-
tion model is no more applicable as the distance would be
too long to accommodate exon-bridging interactions.
Therefore, only exons that were spliced out individually
were compared to the mean values. The SSPNN program
gave the exons that can become skipped a significantly
lower score (0.63, p = 0.03) at the acceptor site, compared
to the mean NF1 acceptor score for all NF1 exons (0.81).
No such correlation could be found at the donor site.
Exon bridging interactions may occur less efficiently as a
result of weak binding of splice factors at the acceptor site,
thus modulating the splicing efficiency. This finding un-
derlines the importance of the acceptor site in splice site
selection. This is in agreement with a recent study [22] in
which it was shown that mutating the acceptor site to a
stronger site was more effective for full intron splicing of
an alternative intron, than strengthening the donor site.
Likewise, there was an inverse relationship found between
the length of the polythimidine tract, which influences the
acceptor strength, at the exon 9 acceptor site and the pro-
portion of exon 9 deleted CFTR mRNA transcripts [23].
Our results indicate that acceptor splice site strength is an
important parameter in the regulation of NF1 splicing.
Role of branch point position and strength
Some studies have pointed to the importance of the
branch point in alternative splicing [24,25]. The distance
between the branch point and the 3' splice site and the
base pairing of the branch point with the U2RNA is im-
portant for splicing. The majority of branch points used in
vertebrate splicing are between 10 and 50 nucleotides up-
stream from the acceptor splice site. We have analysed 1)
the position of the putative branch point sequence and 2)
the match of the putative branch point sequence to the
loosely defined consensus YURAY. We developed a pro-
gram to calculate the strength of a branch point. The re-
gion between -50 and -10 upstream from the acceptor site
was examined for a branch point signal and the corre-
sponding branch point score was calculated (Table 1). A
relatively low score points to a suboptimal branch point
or to a branch point situated outside the chosen window
(-50, -10). Branch points located at long distances are also
suboptimal. However, mean branch point strength (TableBMC Genomics 2002, 3 http://www.biomedcentral.com/1471-2164/3/13
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Table 1: Neurofibromatosis Type 1 splicing parameters.
Exon nr. Frame Score acceptor Score donor Branch point score Branch point position
Exon 1 IF 0.91
Exon 2 IF 1.00 0.99 0.84 38
Exon 3 IF 0.79 1.00 0.99 31
Exon 4a OF 0.81 0.99 0.77 16
Exon 4b OF 1.00 1.00 0.97 41
Exon 4c OF 0.66 1.00 0.87 38
Exon 5 OF 0.99 0.99 0.74 49
Exon 6 OF 0.55 1.00 0.97 30
Exon 7 IF 0.64 0.93 0.87 23
Exon 8 IF 0.68 0.99 0.74 33
Exon 9 IF 1.00 0.99 0.90 37
Exon 9br IF 0.05 0.96 0.82 36
Exon 10a IF 0.98 0.99 0.92 47
Exon 10b IF 0.98 0.86 0.98 26
Exon 10c IF 0.99 0.99 0.82 27
Exon 11 OF 0.01 0.79 0.73 42
Exon 12a OF 0.23 1.00 0.82 36
Exon 12b IF 0.98 0.19 0.87 20
Exon 13 OF 0.72 0.99 0.71 28
Exon 14 OF 0.65 0.99 0.88 36
Exon 15 IF 0.97 1.00 0.88 34
Exon 16 IF 0.46 0.92 0.97 43
Exon 17 OF 0.99 1.00 0.82 35
Exon 18 IF 0.98 0.99 0.98 32
Exon 19a IF 0.98 0.94 0.67 43
Exon 19b IF 0.99 0.13 0.90 31
Exon 20 OF 0.96 0.79 0.82 43
Exon 21 OF 0.90 0.99 0.69 26
Exon 22 IF 0.99 0.92 0.99 23
Exon 23-1 OF 0.99 0.75 0.76 28
Exon 23-2 OF 1.00 0.98 0.74 38
Exon 23-a IF 0.95 0.98 0.90 15
Exon 24 IF 0.99 0.41 0.87 29
Exon 25 OF 0.91 0.88 0.98 29
Exon 26 IF 0.79 1.00 0.97 20
Exon 27a IF 0.49 0.53 0.97 31
Exon 27b IF 0.99 0.99 0.90 27
Exon 28 OF 1.00 0.98 0.97 32
Exon 29 OF 0.81 0.97 0.82 38
Exon 30 OF 0.98 0.96 0.75 18
Exon 31 OF 0.98 0.58 0.97 19
Exon 32 IF 0.78 0.99 0.77 33
Exon 33 OF 0.99 1.00 0.74 27
Exon 34 OF 0.93 0.41 0.76 24
Exon 35 OF 0.98 1.00 0.90 46
Exon 36 OF 0.56 0.89 0.72 28
Exon 37 IF 0.09 0.99 0.82 42
Exon 38 IF 0.93 1.00 0.89 29
Exon 39 OF 0.47 0.82 0.90 29
Exon 40 IF 1.00 0.70 0.89 35
Exon 41 OF 0.98 1.00 0.84 23
Exon 42 OF 0.98 0.73 0.82 27
Exon 43 IF 0.99 0.77 0.84 14
Exon 44 OF 0.91 0.71 0.82 28
Exon 45 OF 0.52 0.96 0.74 20
Exon 46 OF 1.00 0.63 0.90 34
Exon 47 OF 0.80 1.00 0.82 11
Exon 48 OF 0.82 0.98 0.90 16BMC Genomics 2002, 3 http://www.biomedcentral.com/1471-2164/3/13
Page 6 of 10
(page number not for citation purposes)
2) was not significantly lower (p = 0.411) for the exons as-
sociated with skipping.
Role of secondary structure in splice site selection
Recently, it was suggested that NF1 exon skipping events
could be explained by structural alterations in possible
higher free-energy structures of the pre-mRNA at the do-
nor site [19]. Here in, it was hypothesised that when an al-
ternative structure is too different from the lowest free-
energy structure (ground state) this sequence is not recog-
nised by the splicing machinery and that, as a conse-
quence, the corresponding exon becomes skipped. We
further elaborated this hypothesis by comparing the low-
est free energy structures of the donor- and acceptor sites
of all exons that were prone to skipping (bold in Table 1)
to their first higher free-energy structures using the mfold
program [26,27]. Some structures showed remarkable al-
terations between both energy states, but many others did
not at all. A representative example is given in figure 3
where a striking structural change was found between the
energy states of the donor of exon 7 (Fig. 3A,3B). On the
other hand, very similar structures were obtained for the
donor of exon 4b (Fig. 3C,3D) although this exon was
shown to be skipped in a significant part of the mRNA in
several tissues (unpublished results) using the highly ac-
curate real-time PCR technique [28]. Moreover, when the
window is displaced over a few nucleotides, as exempli-
fied here for exon 8, the ground state alters considerably,
(Fig. 3E,3F), demonstrating the difficulty of assigning sig-
Exon 48 a IF 0.16 0.90 0.89 32
Exon 49 OF 1.00 0.78 24
NF1-insE4a-2 OF 0.51 0.99 0.90 10
NF1-∆ 100_835 OF 0.81 0.48 0.87 13
NF1-∆ 64_1530 IF / / 0.82 30
NF1-∆ 1744_2823 IF / / 0.84 20
NF1-∆ 1760_2916 OF / / 0.83 41
NF1-∆ 2410_2638 OF 0.03 1.00 0.69 24
NF1-∆ 2618_2850 OF 0.99 0.95 0.82 35
NF1-∆ 2671_3086 OF / / 0.77 20
NF1-∆ 2761_3258 IF 0.81 0.07 0.77 25
NF1-∆ 3315_3353 IF / 0.13 0.80 41
NF1-
3975+10325ins78
IF 0.76 0.99 0.92 32
NF1-4515-14ins14 OF 0.92 1.00 0.97 17
NF1-
4772+48940ins89
OF 0.01 0.93 0.77 22
NF1-
4772+15759ins51
IF 0.14 0.98 0.90 30
NF1-∆ 4773_5065 OF 0.84 0.99 1.00 37
NF1-∆ 5152_6937 OF 0.47 0.72 0.82 24
NF1-∆ 5206_6937 OF 0.47 0.98 0.82 24
NF1-∆ 5701_6946 OF / / 0.82 33
NF1-5749+3800ins67 OF 0.28 0.35 0.89 28
NF1-∆ 6365_6479 OF 0.82 1.00 0.69 17
NF1-∆ 6859_6934 OF / 0.99 0.82 21
NF1-
7126+4386ins111
IF 0.52 0.95 0.78 44
NF1-∆ 7605_7675 OF 0.91 / 0.82 22
NF1-8314+1584ins77 OF 0.99 0.92 0.80 20
'/': No score can be obtained by SSPNN, not even at the lowest threshold. Exons in bold were detected to skip as individual exon in some tran-
scripts. Underscored scores have values of <0.70.
Table 1: Neurofibromatosis Type 1 splicing parameters. (Continued)
Table 2: Mean splicing parameters for exons that splice out in 
part of the mRNA (A) versus the mean of all NF1 exons (B).
acceptor score donor score branch point 
score
ABABAB
mean 0.63 0.81 0.90 0.88 0.83 0.85
p-value 0.030 0.704 0.411BMC Genomics 2002, 3 http://www.biomedcentral.com/1471-2164/3/13
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Figure 3
Simulations of secondary structure. Secondary structure of the sequence surrounding the donor site of exon 7 (A, B),
exon 4b (C, D) and exon 8 (E-F). A and C: lowest free-energy structures; B and D: first higher energy-structure; E and F: pre-
diction using a window of (-50, +50) (E) or (-56, +44) (F) with respect to the splice site.
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nificance to these in silico results. These data indicate that
one has to be extremely careful when correlating exon
skipping events to secondary structure predictions. Limi-
tations of the mathematical model, uncertainties in the
thermodynamic parameters and influences of the second-
ary structure in vivo by specific interactions of RNA-pro-
tein complexes limit the prediction capacities of
secondary structure by these programs.
On the other hand, comparison of the ground state of a
mutant donor site, as was done for G1185+1U and
G1185+1A in [19], to the higher energy structure of the
normal donor is superfluous to explain skipping. It is well
known that splice sites mutated at their highly conserved
AG-GT bases are not recognised anymore by the splicing
machinery since recognition e.g. of the splice donor by the
U1snRNP is mainly directed by RNA-RNA base pairing
[29,30].
Conclusions
The data presented in this study indicate that splicing in
NF1 is extremely complex. Although several alternative
transcripts have been found previously for the NF1 gene
[9–12], we identified multiple novel NF1 splice variants
and made a survey of them. This large catalogue of vari-
ants detected in one single gene allowed to perform a
comparative analysis of the factors involved in splice reg-
ulation in order to explain the observed variants. We per-
formed an extensive analysis of different splicing
parameters. These include the strength of the 5' and 3'
splice site, the branch point strength and secondary struc-
ture predictions at the donor and acceptor site. On the ba-
sis of the analysed features we can conclude that an
interplay of various factors is involved in regulation of
NF1 splicing. Competition between the alternative splice
sites depends on the relative quality of the different con-
stitutive splice signals and we found that the acceptor
strength probably plays a major role in this regulation.
The functional significance of the transcripts identified in
this study still remains unclear. What fraction of the splic-
ing represents 'noise', caused by the relaxation of the RNA
splicing, is currently unknown. Although the RNA was ex-
tracted immediately after blood drawing, excluding as far
as possible influences due to stress factors, some splice
events occurred at non-consensus splice sites and proba-
bly represent 'aberrant' splicing. However, some of these
novel identified transcripts could potentially encode pro-
teins of different sizes and may have distinct roles. Further
research was started to analyse tissue-specific expression
of several transcripts. Preliminary results show that some
transcripts are highly expressed in specific tissues, demon-
strating that splicing in NF1 may be regulated in a tissue
specific manner. Further analysis of these transcripts is
needed and it will remain a challenging task to elucidate
the biological significance of all of them.
Materials and methods
RNA isolation and cDNA preparation
RNA was isolated from fresh blood leukocytes from two
normal individuals using TRIzol LS Reagent (Invitrogen)
according to the manufacturer's instructions. RNA extrac-
tion was performed immediately after blood drawing, ex-
cluding as far as possible influences due to stress factors.
Total RNA (2 µg) was reverse transcribed using Super-
Script II Reverse transcriptase (Invitrogen) and random
hexamers (Amersham Biosciences).
RT-PCR library formation and PCR analysis
Primers used for the amplification of the total NF1 cDNA
in 5 overlapping fragments were as described [17]. Reac-
tions were performed as described [13]. The PCR products
were cloned in the pCR2.1-TOPO-vector (Invitrogen) and
transformed into TOP-10F' cells. The colonies were lysed
and the subcloned fragments were reamplified with the
same primers. The five NF1 fragments (NF1-F1 to NF1-F5)
were digested subsequently with different restriction en-
zymes: ScrfI, StyI, and BsrI for NF1-F1, HaeIII and AvaII for
NF2-F2, HaeII for NF1-F3 and NF1-F5, and AvaII for NF1-
F4. All transcripts with a different restriction pattern were
sequenced (primer sequences available upon request) us-
ing the Thermo Sequenase fluorescent labelled primer cy-
cle sequencing kit (Amersham Biosciences) and analysed
on an ALF-express automated DNA sequencer (Amersham
Biosciences).
Nomenclature for the description of the different NF1 
transcripts
In order to clearly describing the identity (ID) of the tran-
scripts, following nomenclature was used:
• The ID of all transcript variants start with 'NF1' followed
by '-'.
• Sequence changes are all described at the RNA level,
with 1 = first base of methionine (ATG) at the start. Num-
bering system for insertions are based on the NF1 genom-
ic sequence (Genbank Accession Nr. AC004526).
• Deletions are designated with the symbol '∆ ', insertions
with 'ins'.
• Deletions are described with a '_' separating the first and
the last deleted exon.
• Skipping of a complete exon is designated by an 'E' pre-
ceding the exon number. Two consecutive deleted exons
are separated by '/'. When more than two consecutive ex-
ons were deleted, the first and the last deleted exon are
separated by a '_' character, non-consecutive exons are
separated by a ',' character to indicate that intermediate ex-
ons are not deleted.BMC Genomics 2002, 3 http://www.biomedcentral.com/1471-2164/3/13
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• Insertions are described by a '+' or a '-' after the nucle-
otide flanking the insertion site, followed by the position
of the first inserted nucleotide of the intron (beginning of
intron = +1, for insertions flanking the acceptor site: end
of preceding intron = -1), followed by 'ins' and the length
of the inserted sequence.
• Insertions of a complete intron are designated by 'IVS'
preceding the intron number.
• When more than one change was detected, these chang-
es are described between square brackets, separated by a ','
character.
Splice site scores
The sequence environment of all donor- and acceptor
sites was analysed using Splice Site Prediction by Neural
Network (SSPNN, URL address:  [http://www.fruitfly.org/
seq_tools/splice.html] ).
Branch point scores
We searched for branch point sequences in a window of -
50, -10 with respect to the acceptor site. A program was
written in DELPHI to calculate the strength of a branch
point. Every 5-nucleotide sequence within the window
was evaluated as a potential branch point. The 'standard'
branch point sequence weight-table [4] was used to assign
a score at every 5-nucleotide sequence within the window.
The computed score reflects how closely it resembles
known branch point sequences. The sequence with the
highest score was selected as the 'putative' branch point.
Secondary structures
The mfold computer program version 3.0  [http://bioin-
fo.math.rpi.edu/~mfold/rna/form1.cgi]  was used to pre-
dict the RNA secondary structure and to calculate the
folding free energy [26,27]. We have computed the mini-
mum-free-energy structures from all the donor- and ac-
ceptor sites of the 60 exons of NF1 within a window of
100 bp. It has been proposed [31] that there is a window
of about 100 nucleotides after transcription where the
pre-mRNA is free to fold. The size of this window would
be defined by the time taken for the protein complexes to
bind as the nascent RNA emerges.
Statistical analysis
The one-way ANOVA test was used to assess significance
in the comparison of mean values.
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